AQR Capital Management LLC acquires 16,251 shares of AtriCure, Inc. (NASDAQ:ATRC)

AQR Capital Management LLC grew its stake in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 38.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,738 shares of the medical device company’s stock after purchasing an additional 16,251 shares during the period. AQR Capital Management LLC’s holdings in AtriCure were worth $1,337,000 at the end of the most recent reporting period.

A number of other large investors have added to or reduced their stakes in ATRC. Comerica Bank boosted its holdings in shares of AtriCure by 70.5% in the first quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 1,043 shares during the last quarter. Quest Partners LLC raised its position in AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after buying an additional 1,626 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of AtriCure in the fourth quarter valued at approximately $213,000. Mount Yale Investment Advisors LLC bought a new position in AtriCure in the first quarter valued at approximately $224,000. Finally, ProShare Advisors LLC raised its position in AtriCure by 8.5% in the first quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company’s stock worth $255,000 after purchasing an additional 659 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s shares.

Insider Trading at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $24.07, for a total transaction of $84,245.00. Following the completion of the sale, the director now directly owns 8,970 shares of the company’s stock, valued at approximately $215,907.90. This represents a 0.00 % decrease in ownership of the shares. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. Corporate insiders own 3.20% of the company’s shares.

AtriCure stock performance

Shares of ATRC stock opened at $27.05 on Friday. The company has a fifty day simple moving average of $25.82 and a two hundred day simple moving average of $24.25. The company has a quick ratio of 2.93, a current ratio of 4.13, and a debt-to-equity ratio of 0.16. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -33.81 and a beta of 1.44. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.00.

AtriCure (NASDAQ:ATRC – Get Free Report ) last posted its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The company had revenue of $116.27 million for the quarter, compared to analyst estimates of $116.24 million. AtriCure had a negative net margin of 9.33% and a negative return on equity of 8.39%. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period last year, the company posted ($0.12) earnings per share. Analysts predict that AtriCure, Inc. will record -0.77 earnings per share for the current year.

Analyst upgrades and downgrades

Several brokerages recently commented on ATRC. Needham & Company LLC lowered their price objective on AtriCure from $40.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. StockNews.com upgraded AtriCure from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. Piper Sandler cut their price target on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. JPMorgan Chase & Co. decreased their price objective on AtriCure from $34.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Finally, BTIG Research cut their price target on AtriCure from $58.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. AtriCure has a consensus rating of “Moderate Buy” and an average target price of $42.44, according to MarketBeat.com.

Read our latest research report on AtriCure

AtriCure Company Profile

(Free report)

AtriCure, Inc develops, manufactures and sells devices for surgical cardiac tissue ablation, left atrial appendage exclusion and temporary peripheral nerve ablation pain blockade to medical centers in the United States, Europe, Asia-Pacific and internationally. The company offers Isolator Synergy Clamps, disposable radio frequency products; multi-functional pens and linear ablation devices, such as the MAX Pen device, which allows surgeons to assess cardiac arrhythmias, perform pacing, detection and temporary pacing, and ablate cardiac tissue with the same device; and the Coolrail device, which allows users to achieve longer linear ablation lines.

Featured stories

Want to see what other hedge funds own ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for AtriCure, Inc. (NASDAQ:ATRC – Free Report).

Get news and reviews for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.